Hewlett Packard Enterprise's (NYSE: HPE) blowout Q2 earnings and accelerated long-term targets expose a severe valuation mismatch in the artificial intelligence (AI) hardware sector as enterprise adoption broadens beyond hyperscalers.
With agentic AI workloads rapidly migrating to the network edge.... |
Good MorningU.S. stocks split sharply Thursday as a tech selloff collided with leadership rotation, leaving investors to weigh whether AI spending breadth can offset fresh questions on chip-cycle profitability. The Dow pushed to a record while the Nasdaq slipped. Money flowed into health care, financials, and consumer names as concentration risk finally expressed itself.
Macro tailwinds aided the rotation. Oil and Treasury yields eased after an Israel-Lebanon ceasefire pulled a geopolitical tail off the table, supporting rate-sensitive cyclicals and easing input-cost worries for consumer names. Attention turns to Friday's May payrolls print, where a soft read would firm expectations for a more accommodative Fed path.
Corporate signals reinforced the divide. Broadcom slid double digits on weak margin commentary and CrowdStrike fell sharply post-earnings, feeding the AI-profitability overhang. Hewlett Packard Enterprise's raised long-term outlook pointed to demand widening beyond hyperscalers, lifting Super Micro and returning legacy hardware to the AI conversation. UnitedHealth led the non-tech bid as Quantinuum's upsized IPO priced above range. Traders are watching Friday's payrolls and whether rotation can carry beyond NVIDIA-adjacent leadership. Featured: This 38 Dollar Fund Holds Nvidia CrowdStrike and Other Top AI Names (Ad) 
| Technology | |
Hewlett Packard Enterprise's (NYSE: HPE) blowout Q2 earnings and accelerated long-term targets expose a severe valuation mismatch in the artificial intelligence (AI) hardware sector as enterprise adoption broadens beyond hyperscalers.
With agentic AI workloads rapidly migrating to the network edge... Read the Full Story |
| From Our Partners | | Barrick Mining has spent decades building one of Nevada's richest gold districts, anchored by Fourmile, Goldrush, and Cortez Hills, deposits that could hold up to 60 million ounces of gold.
One overlooked explorer controls 142 claims bordering Fourmile and sitting less than a mile from Goldrush. New geological modeling aims to reveal what's beneath this largely untested ground, while a planned 5% royalty spin-off could give shareholders a separate stake in the project. | | Read the full report before the next catalyst hits |
| Industrials | |
Power consumption is the hardest physical limit on artificial intelligence (AI) scaling. As tech giants race to build the next generation of power-hungry data centers, a legacy manufacturer known for residential backup generators has executed a brilliant strategic pivot.
A strategic pivot that now... Read the Full Story |
| Healthcare | |
Medtronic's (NYSE: MDT) primary catalyst as mid-year approaches is that headwinds are not impairing results as much as feared. Rising costs, margin compression, and general uncertainty linked to macroeconomic headwinds were reflected in the company's June 3 earnings results, but the results were i... Read the Full Story |
| From Our Partners | | Each morning, the Wave Software scans the market for stocks quietly building momentum over days or weeks, then narrows the list to a single name showing signs of an imminent move.
From there, it outlines specific options criteria designed to match that potential move, giving traders a complete setup before the market opens.
No guesswork, no scanning countless charts, just one focused opportunity to evaluate each day. | | See how the Wave Software pinpoints daily trade opportunities before 9 am. |
| Technology | |
GitLab’s (NASDAQ: GTLB) Q1 earnings release left something to be desired, but it was still a healthy report. The primary concerns center on executing the Act 2 turnaround, which appears to be gaining traction. Act 2 is focused on elevating GitLab from a simple developer tool to an AI-empowered orch... Read the Full Story |
| Industrials | |
There are pullbacks that signal something is wrong, and there are pullbacks that reflect a stock catching its breath after an extraordinary run. For Rocket Lab (NASDAQ: RKLB), the nearly 24% decline from its 52-week high of $151 to Wednesday's close of $115 looks far more like the latter.
The stock... Read the Full Story |
| From Our Partners | | A 60-minute morning window is catching traders' attention for one reason: it doesn't depend on market direction.
Place a quick trade before 10 am, then step away. Sixty minutes later, the setup has already done its work.
The strategy targets a 50 percent return potential on a $1,000 stake, though results vary and some trades won't work out. | | Discover how to apply this 60 minute trading window today |
| Consumer Discretionary | |
Late last week, a Blue Origin rocket exploded at Cape Canaveral just days before it was due to launch a batch of Amazon.com Inc’s (NASDAQ: AMZN) low-Earth-orbit broadband satellites, seriously damaging the launchpad in the process. The market reaction in the days since has been predictable.
Even a... Read the Full Story |
| Industrials | |
The SpaceX (NASDAQ: SPCX) IPO is the most talked-about market event in years. But Chris Graebe, an analyst at Weiss Ratings, says the investors who will really profit already got in—and it wasn't recently.
Graebe has spent the last several years guiding everyday investors into private companies bef... Read the Full Story |
| Consumer Discretionary | |
If the widely publicized Trump accounts come to fruition, the next generation of teenagers may have vastly different ideas on where to spend their money. But that’s an issue for 2036 or beyond. In 2026, it’s important for investors to pay attention to the brands that are capturing their eyeballs an... Read the Full Story |
| Consumer Discretionary | |
Forget Bitcoin, high-speed memory is the new digital gold, and companies that supply data storage have seen their stock prices explode this year.
Memory has become a crucial bottleneck as AI training programs produce massive amounts of data, and memory companies like Micron Technology Inc. (NASDAQ:... Read the Full Story |
| Consumer Discretionary | |
Ulta Beauty (NASDAQ: ULTA) has hurdles like any consumer company this year, but it is navigating the scene well, and its strategies are working. Focused on increased store count, international expansion, acquisitions, and expanding product lines, the company is growing, outperforming estimates, and... Read the Full Story |
| Friday's Early Bird Stock Of The Day Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana. | Should I Buy Eli Lilly and Company Stock? LLY Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Eli Lilly and Company was last updated on Sunday, August 30, 2026 at 6:03 PM.
Eli Lilly and Company Bull Case -
The company recently reported earnings per share (EPS) of $8.38, significantly exceeding analysts' expectations, indicating strong financial performance.
-
Eli Lilly and Co has a robust net margin of over 33%, suggesting efficient management and profitability, which can lead to higher returns for investors.
-
The stock has shown impressive revenue growth, with a year-over-year increase of nearly 48%, reflecting strong demand for its products.
-
The current stock price is around $1,190, which is near its twelve-month high, indicating strong market confidence in the company's future prospects.
-
The company has a solid dividend payout ratio of 23.22%, providing a steady income stream for investors through its quarterly dividends.
Eli Lilly and Company Bear Case -
The stock has a relatively high price-to-earnings (P/E) ratio of 39.23, which may suggest that it is overvalued compared to its earnings potential.
-
With a beta of 0.51, the stock is less volatile than the market, which may limit potential gains during bullish market conditions.
-
The company has a debt-to-equity ratio of 1.41, indicating a higher level of debt compared to equity, which could pose risks in economic downturns.
-
Insider selling activity has been noted, with significant shares sold recently, which may raise concerns about the company's future outlook from those closest to it.
-
The dividend yield is relatively low at 0.6%, which may not be attractive for income-focused investors compared to other investment opportunities.
| | View Today's Stock Pick |
|
| |
|
|
